You are here

  • Home
  • Archive
  • Volume 78, Issue 10
  • Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Citation Tools

Article menu
XML
Rheumatoid arthritis
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tanaka Y, Takeuchi T, Tanaka S, et al
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Annals of the Rheumatic Diseases 2019;78:1320-1332.